HIV Prevention Research & Development Investments, 2000–2015 Investment Priorities to Fund Innovation in a Challenging Global Health Landscape

December 2016 - Reports, Guidelines, and Tools

View Full Edition Send to a Friend

HIV Resource Tracking for HIV Prevention Research and Development (October 2016).

This report examines trends in research and development (R&D) investments and spending for biomedical HIV prevention interventions. This report highlights findings for 2015 and analyzes trends over the past 15 years. Findings include:

  • Between 2014 and 2015, basic research accounted for 21 percent of investments; pre-clinical research experienced a slight increase from 42 to 44 percent. Implementation science accounted for approximately 12 percent of investments.
  • Private-sector contributions included expansion of biomedical prevention options. Commercial sector implementation research spending increased 36 percent between 2014 and 2015.
  • Seventy percent of the total USD$1.2 billion invested in 2015 come from the U.S. public sector, chiefly the National Institutes of Health. The Bill & Melinda Gates Foundation accounted for 80 percent of charitable giving. More funding diversity is needed to increase funding stability.
  • The end of the Millennium Development Goals has resulted in a $2 billion reduction in development assistance for health spending—the first reduction since 2000. Investments from development agencies in R&D for HIV fell by $11 million in 2015. To end the epidemic, R&D on HIV prevention must be reprioritized on the global agenda.
  • Lower- and upper-middle-income countries mainly rely upon donor aid and require assistance to identify domestic funding sources for R&D on HIV prevention. 

Search the Prevention Update Archive